Himalaya Nutravedics India IPO

Himalaya Nutravedics IPO comprises a total issue size of 24,99,600 shares. The net offer to the public is 23,73,600 shares, after excluding 1,26,000 shares allotted on a firm basis. Of the Net offer 11,84,400 (49.90%) are allocated to QIB , 3,56,400 (15.02%) allocated to NII 8,32,800 (35.09%) allocated to RII .

Investors can bid for a minimum of 2,400 shares and in multiples of 1,200 shares thereof.

Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing and distribution of Ayurvedic and nutraceutical formulations in India and also undertakes third-party contract manufacturing for other Ayurvedic and nutraceutical companies. The Company manufactures a diversified portfolio comprising classical (Shastric) Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements. Its products are available in multiple dosage forms, including soft gelatin capsules, hard gelatin capsules, tablets, liquid orals and medicated oils. The products cater to therapeutic and wellness areas such as gut health, cardiac and metabolic wellness, diabetes management, pain management, immunity, women's wellness and general wellness.

Himalaya Nutravedics operates through a hybrid business model comprising its own branded products and third-party contract manufacturing. Under its own-brand business, the Company develops, manufactures and markets Ayurvedic and nutraceutical products, while its third-party manufacturing business provides formulation, manufacturing, packaging and dispatch services based on client specifications. As of March 31, 2026, its own-brand business contributed approximately ₹2,202.54 lakh, representing about 51.14% of total revenue.

The Company operates an integrated manufacturing facility in Hyderabad, Telangana, where formulation, production, quality control, packaging and finished-goods release are carried out internally. The facility is compliant with WHO-GMP standards and holds registrations and licences from AYUSH and FSSAI, along with certifications including ISO 9001:2015, ISO 22000:2018, HACCP, HALAL and KOSHER.

As of July 31, 2026, the Company had 86 full-time employees across marketing, factory, finance, quality, compliance and administration functions.

Competitive Strengths

Geographic expansion across India.

Long-standing supplier and customer relationships.

Integrated multi-dosage manufacturing capabilities.

Doctor acceptance supported by product performance.

Broad therapeutic coverage across Ayurvedic and nutraceutical segments

Himalaya Nutravedics India Ltd.'s revenue increased by 105% and profit after tax (PAT) rose by 231% between the financial year ending with March 31, 2026 and March 31, 2025.

The Himalaya Nutravedics IPO is subscribed 2.33 times on September 24, 2026 6:54:56 PM (Day 3). The public issue subscribed 2.56 times in the individual investors category, 1.00 times in the QIB category, and 3.58 times in the NII category. Check Day by Day Subscription Details (Live Status)

Reload

Total Applications: 1,039

*Market Maker portion is not included to NII/HNI.